EP0374765B1 - 2,3-Disubstituted-4-hydroxyquinoline derivatives and process for preparing the same - Google Patents
2,3-Disubstituted-4-hydroxyquinoline derivatives and process for preparing the same Download PDFInfo
- Publication number
- EP0374765B1 EP0374765B1 EP19890123280 EP89123280A EP0374765B1 EP 0374765 B1 EP0374765 B1 EP 0374765B1 EP 19890123280 EP19890123280 EP 19890123280 EP 89123280 A EP89123280 A EP 89123280A EP 0374765 B1 EP0374765 B1 EP 0374765B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- nonenyl
- solution
- trans
- mmols
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 2,3-Disubstituted-4-hydroxyquinoline Chemical class 0.000 title claims description 33
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 229940058961 hydroxyquinoline derivative for amoebiasis and other protozoal diseases Drugs 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 229910052744 lithium Inorganic materials 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910011687 LiCu Inorganic materials 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 74
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- 239000002904 solvent Substances 0.000 description 49
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 238000001035 drying Methods 0.000 description 14
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 230000003042 antagnostic effect Effects 0.000 description 10
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- NLHYITINDOLKPY-UHFFFAOYSA-N (2-formyl-3-methylquinolin-4-yl) acetate Chemical compound C1=CC=C2C(OC(=O)C)=C(C)C(C=O)=NC2=C1 NLHYITINDOLKPY-UHFFFAOYSA-N 0.000 description 5
- JYMBDXKPGVARBH-GXDHUFHOSA-N [3-methyl-2-[(e)-non-1-enyl]quinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(C)C(/C=C/CCCCCCC)=NC2=C1 JYMBDXKPGVARBH-GXDHUFHOSA-N 0.000 description 5
- RHAFNLXWELMNIT-UHFFFAOYSA-N [6-fluoro-2-(1-hydroxynon-2-ynyl)-3-methylquinolin-4-yl] acetate Chemical compound C1=C(F)C=C2C(OC(C)=O)=C(C)C(C(O)C#CCCCCCC)=NC2=C1 RHAFNLXWELMNIT-UHFFFAOYSA-N 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CSUHMFWRCJCPEG-UHFFFAOYSA-N [2-(1-hydroxynon-2-ynyl)-3-methylquinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(C)C(C(O)C#CCCCCCC)=NC2=C1 CSUHMFWRCJCPEG-UHFFFAOYSA-N 0.000 description 4
- FMJBLFZRZZAORU-MDZDMXLPSA-N [3-methyl-2-[(e)-non-2-enyl]quinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(C)C(C/C=C/CCCCCC)=NC2=C1 FMJBLFZRZZAORU-MDZDMXLPSA-N 0.000 description 4
- LSPXHMXLSFRQNI-MDZDMXLPSA-N [6-fluoro-2-[(e)-1-hydroxynon-2-enyl]-3-methylquinolin-4-yl] acetate Chemical compound C1=C(F)C=C2C(OC(C)=O)=C(C)C(C(O)/C=C/CCCCCC)=NC2=C1 LSPXHMXLSFRQNI-MDZDMXLPSA-N 0.000 description 4
- NQNLSYAUHZRROM-ZHACJKMWSA-N [6-fluoro-3-methyl-2-[(e)-non-1-enyl]quinolin-4-yl] acetate Chemical compound C1=C(F)C=C2C(OC(C)=O)=C(C)C(/C=C/CCCCCCC)=NC2=C1 NQNLSYAUHZRROM-ZHACJKMWSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- UMIPWJGWASORKV-UHFFFAOYSA-N oct-1-yne Chemical compound CCCCCCC#C UMIPWJGWASORKV-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
- QGVIUPJIZVYWDJ-UHFFFAOYSA-N (2,3-dimethylquinolin-4-yl) acetate Chemical compound C1=CC=C2C(OC(=O)C)=C(C)C(C)=NC2=C1 QGVIUPJIZVYWDJ-UHFFFAOYSA-N 0.000 description 3
- DRFDHZVLCVQNJC-UHFFFAOYSA-N (6-fluoro-2-formyl-3-methylquinolin-4-yl) acetate Chemical compound C1=C(F)C=C2C(OC(=O)C)=C(C)C(C=O)=NC2=C1 DRFDHZVLCVQNJC-UHFFFAOYSA-N 0.000 description 3
- AVFFIYNMABIPEH-UHFFFAOYSA-N 2-(1-hydroxynon-2-ynyl)-3-methyl-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(C)C(C(O)C#CCCCCCC)=NC2=C1 AVFFIYNMABIPEH-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- XICKFFMQHHMRFO-UHFFFAOYSA-N 3-methyl-2-(2-nonenyl)-4-quinolinone Natural products C1=CC=C2C(O)=C(C)C(CC=CCCCCCC)=NC2=C1 XICKFFMQHHMRFO-UHFFFAOYSA-N 0.000 description 3
- RJCVLWMQJQFPFD-UKTHLTGXSA-N 3-methyl-2-[(e)-non-1-enyl]-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(C)C(/C=C/CCCCCCC)=NC2=C1 RJCVLWMQJQFPFD-UKTHLTGXSA-N 0.000 description 3
- GOWYCDMJAZDPTH-CMDGGOBGSA-N 3-methyl-2-[(e)-non-2-enyl]-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(C)C(C/C=C/CCCCCC)=NC2=C1 GOWYCDMJAZDPTH-CMDGGOBGSA-N 0.000 description 3
- RJCVLWMQJQFPFD-LCYFTJDESA-N 3-methyl-2-[(z)-non-1-enyl]-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(C)C(\C=C/CCCCCCC)=NC2=C1 RJCVLWMQJQFPFD-LCYFTJDESA-N 0.000 description 3
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical class C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 description 3
- PKBLRGHGIZTZAN-UHFFFAOYSA-N 6-fluoro-2-(1-hydroxynon-2-ynyl)-3-methyl-3h-quinolin-4-one Chemical compound C1=C(F)C=C2C(=O)C(C)C(C(O)C#CCCCCCC)=NC2=C1 PKBLRGHGIZTZAN-UHFFFAOYSA-N 0.000 description 3
- QCHRNMFGRYJGEL-CMDGGOBGSA-N 6-fluoro-2-[(e)-1-hydroxynon-2-enyl]-3-methyl-3h-quinolin-4-one Chemical compound C1=C(F)C=C2C(=O)C(C)C(C(O)/C=C/CCCCCC)=NC2=C1 QCHRNMFGRYJGEL-CMDGGOBGSA-N 0.000 description 3
- LVRSPTSXFMXOAK-MDZDMXLPSA-N 6-fluoro-3-methyl-2-[(e)-non-1-enyl]-3h-quinolin-4-one Chemical compound C1=C(F)C=C2C(=O)C(C)C(/C=C/CCCCCCC)=NC2=C1 LVRSPTSXFMXOAK-MDZDMXLPSA-N 0.000 description 3
- CQCPNGXQPTXVMS-CMDGGOBGSA-N 6-fluoro-3-methyl-2-[(e)-non-2-enyl]-3h-quinolin-4-one Chemical compound C1=C(F)C=C2C(=O)C(C)C(C/C=C/CCCCCC)=NC2=C1 CQCPNGXQPTXVMS-CMDGGOBGSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- OXUANWIIZSFBJL-NTEUORMPSA-N [2-[(e)-1-hydroxynon-2-enyl]-3-methylquinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(C)C(C(O)/C=C/CCCCCC)=NC2=C1 OXUANWIIZSFBJL-NTEUORMPSA-N 0.000 description 3
- JYMBDXKPGVARBH-UVTDQMKNSA-N [3-methyl-2-[(z)-non-1-enyl]quinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(C)C(\C=C/CCCCCCC)=NC2=C1 JYMBDXKPGVARBH-UVTDQMKNSA-N 0.000 description 3
- BOZVFBJOEAQVED-MDZDMXLPSA-N [6-fluoro-3-methyl-2-[(e)-non-2-enyl]quinolin-4-yl] acetate Chemical compound C1=C(F)C=C2C(OC(C)=O)=C(C)C(C/C=C/CCCCCC)=NC2=C1 BOZVFBJOEAQVED-MDZDMXLPSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- BILOJZQJCRZZNV-UHFFFAOYSA-N (2,3-dimethyl-1-oxidoquinolin-1-ium-4-yl) acetate Chemical compound C1=CC=C2C(OC(=O)C)=C(C)C(C)=[N+]([O-])C2=C1 BILOJZQJCRZZNV-UHFFFAOYSA-N 0.000 description 2
- SJZDDNSUIVLYIN-BQYQJAHWSA-N (e)-1-iodooct-1-ene Chemical compound CCCCCC\C=C\I SJZDDNSUIVLYIN-BQYQJAHWSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- LKPMHSZNTIKVBE-MDWZMJQESA-N 2-[(e)-1-hydroxynon-2-enyl]-3-methyl-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(C)C(C(O)/C=C/CCCCCC)=NC2=C1 LKPMHSZNTIKVBE-MDWZMJQESA-N 0.000 description 2
- SUQYEDISUJSMLV-UHFFFAOYSA-N 2-hept-1-enyl-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)CC(C=CCCCCC)=NC2=C1 SUQYEDISUJSMLV-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- REHCIOKTMZBHRW-UHFFFAOYSA-N [2-(chloromethyl)-3-methylquinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(=O)C)=C(C)C(CCl)=NC2=C1 REHCIOKTMZBHRW-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- OBLXVLWZBMAMHE-UHFFFAOYSA-M octyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCC)C1=CC=CC=C1 OBLXVLWZBMAMHE-UHFFFAOYSA-M 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- JYMBDXKPGVARBH-UHFFFAOYSA-N (3-methyl-2-non-1-enylquinolin-4-yl) acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(C)C(C=CCCCCCCC)=NC2=C1 JYMBDXKPGVARBH-UHFFFAOYSA-N 0.000 description 1
- IEERZSAMFOPMES-HJWRWDBZSA-N (z)-3-anilino-2-methylbut-2-enoic acid Chemical class OC(=O)C(/C)=C(/C)NC1=CC=CC=C1 IEERZSAMFOPMES-HJWRWDBZSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- PHQNOZPOKVSQAA-UHFFFAOYSA-N 2-hept-2-enyl-3-methyl-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(C)C(CC=CCCCC)=NC2=C1 PHQNOZPOKVSQAA-UHFFFAOYSA-N 0.000 description 1
- ZNTUDOOZDLMYAG-UHFFFAOYSA-N 2-non-1-enyl-1h-quinolin-4-one Chemical compound C1=CC=C2NC(C=CCCCCCCC)=CC(=O)C2=C1 ZNTUDOOZDLMYAG-UHFFFAOYSA-N 0.000 description 1
- XSJDEBDMKGXAQH-UHFFFAOYSA-N 2-nona-3,6-dienyl-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)CC(CCC=CCC=CCC)=NC2=C1 XSJDEBDMKGXAQH-UHFFFAOYSA-N 0.000 description 1
- DMKGXQQGAAPNOZ-UHFFFAOYSA-N 3-ethyl-2-(1-hydroxynon-2-ynyl)-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(CC)C(C(O)C#CCCCCCC)=NC2=C1 DMKGXQQGAAPNOZ-UHFFFAOYSA-N 0.000 description 1
- WGNLKTQFTFHHGN-NTEUORMPSA-N 3-ethyl-2-[(e)-1-hydroxynon-2-enyl]-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(CC)C(C(O)/C=C/CCCCCC)=NC2=C1 WGNLKTQFTFHHGN-NTEUORMPSA-N 0.000 description 1
- GTZVJJOATRMGPI-GXDHUFHOSA-N 3-ethyl-2-[(e)-non-1-enyl]-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(CC)C(/C=C/CCCCCCC)=NC2=C1 GTZVJJOATRMGPI-GXDHUFHOSA-N 0.000 description 1
- NJCURYJFDRKIMZ-MDZDMXLPSA-N 3-ethyl-2-[(e)-non-2-enyl]-3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)C(CC)C(C/C=C/CCCCCC)=NC2=C1 NJCURYJFDRKIMZ-MDZDMXLPSA-N 0.000 description 1
- 150000004331 4-hydroxyquinolines Chemical class 0.000 description 1
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- OCCHMRQWNFFPIZ-UHFFFAOYSA-N C(C=CCCCCCC)C1=NC2=CC=CC=C2C(=C1CC)OC(C)=O.OC(C#CCCCCCC)C1=NC2=CC=CC=C2C(=C1C)OC(CCC)=O Chemical compound C(C=CCCCCCC)C1=NC2=CC=CC=C2C(=C1CC)OC(C)=O.OC(C#CCCCCCC)C1=NC2=CC=CC=C2C(=C1C)OC(CCC)=O OCCHMRQWNFFPIZ-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- VDRPVFJBGQIRES-UHFFFAOYSA-N [2-(iodomethyl)-3-methylquinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(=O)C)=C(C)C(CI)=NC2=C1 VDRPVFJBGQIRES-UHFFFAOYSA-N 0.000 description 1
- UOITUBNGJVHPNI-XNTDXEJSSA-N [2-[(e)-1-hydroxynon-2-enyl]-3-methylquinolin-4-yl] propanoate Chemical compound C1=CC=C2C(OC(=O)CC)=C(C)C(C(O)/C=C/CCCCCC)=NC2=C1 UOITUBNGJVHPNI-XNTDXEJSSA-N 0.000 description 1
- UOPKAQRVHFWSIA-UHFFFAOYSA-N [3-ethyl-2-(1-hydroxynon-2-enyl)quinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(CC)C(C(O)C=CCCCCCC)=NC2=C1 UOPKAQRVHFWSIA-UHFFFAOYSA-N 0.000 description 1
- CDVHMLUKOWFRAE-RVDMUPIBSA-N [3-ethyl-2-[(e)-non-1-enyl]quinolin-4-yl] acetate Chemical compound C1=CC=C2C(OC(C)=O)=C(CC)C(/C=C/CCCCCCC)=NC2=C1 CDVHMLUKOWFRAE-RVDMUPIBSA-N 0.000 description 1
- XNUMLFUVLUNPAG-SFQUDFHCSA-N [3-ethyl-2-[(e)-non-1-enyl]quinolin-4-yl] butanoate Chemical compound C1=CC=C2C(OC(=O)CCC)=C(CC)C(/C=C/CCCCCCC)=NC2=C1 XNUMLFUVLUNPAG-SFQUDFHCSA-N 0.000 description 1
- QAMSFJFYRXPLER-FOWTUZBSSA-N [3-ethyl-2-[(e)-non-1-enyl]quinolin-4-yl] propanoate Chemical compound C1=CC=C2C(OC(=O)CC)=C(CC)C(/C=C/CCCCCCC)=NC2=C1 QAMSFJFYRXPLER-FOWTUZBSSA-N 0.000 description 1
- RIHIEJULQCWCND-VAWYXSNFSA-N [3-ethyl-2-[(e)-non-2-enyl]quinolin-4-yl] butanoate Chemical compound C1=CC=C2C(OC(=O)CCC)=C(CC)C(C/C=C/CCCCCC)=NC2=C1 RIHIEJULQCWCND-VAWYXSNFSA-N 0.000 description 1
- UONZPLGWGQAULR-VAWYXSNFSA-N [3-ethyl-2-[(e)-non-2-enyl]quinolin-4-yl] propanoate Chemical compound C1=CC=C2C(OC(=O)CC)=C(CC)C(C/C=C/CCCCCC)=NC2=C1 UONZPLGWGQAULR-VAWYXSNFSA-N 0.000 description 1
- YBVWWKXIPRQMQX-LFIBNONCSA-N [3-methyl-2-[(e)-non-1-enyl]quinolin-4-yl] butanoate Chemical compound C1=CC=C2C(OC(=O)CCC)=C(C)C(/C=C/CCCCCCC)=NC2=C1 YBVWWKXIPRQMQX-LFIBNONCSA-N 0.000 description 1
- DTHHUEGHTAAWOV-RVDMUPIBSA-N [3-methyl-2-[(e)-non-1-enyl]quinolin-4-yl] propanoate Chemical compound C1=CC=C2C(OC(=O)CC)=C(C)C(/C=C/CCCCCCC)=NC2=C1 DTHHUEGHTAAWOV-RVDMUPIBSA-N 0.000 description 1
- KNCTXOJLTMJGRZ-ZHACJKMWSA-N [3-methyl-2-[(e)-non-2-enyl]quinolin-4-yl] butanoate Chemical compound C1=CC=C2C(OC(=O)CCC)=C(C)C(C/C=C/CCCCCC)=NC2=C1 KNCTXOJLTMJGRZ-ZHACJKMWSA-N 0.000 description 1
- VPFPPDOQYPCKME-ZHACJKMWSA-N [3-methyl-2-[(e)-non-2-enyl]quinolin-4-yl] propanoate Chemical compound C1=CC=C2C(OC(=O)CC)=C(C)C(C/C=C/CCCCCC)=NC2=C1 VPFPPDOQYPCKME-ZHACJKMWSA-N 0.000 description 1
- RVCUHJNKMKDZPP-UHFFFAOYSA-N [6-fluoro-2-(iodomethyl)-3-methylquinolin-4-yl] acetate Chemical compound C1=C(F)C=C2C(OC(=O)C)=C(C)C(CI)=NC2=C1 RVCUHJNKMKDZPP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- FNENWZWNOPCZGK-UHFFFAOYSA-N ethyl 2-methyl-3-oxobutanoate Chemical compound CCOC(=O)C(C)C(C)=O FNENWZWNOPCZGK-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 239000011356 non-aqueous organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
Definitions
- This invention relates to novel 4-hydroxyquinoline derivatives which have been found during the course of systematic studies of 2,3-disubstituted-4-hydroxyquinoline derivatives and which have antagonistic action on leukotriene D4 and also to a process for chemically preparing same.
- the novel 2,3-disubstituted-4-hydroxyquinoline derivatives of the invention strongly antagonize leukotriene D4 which is energized in the body of mammals in allergic state and has the action of shrinking organs and are thus useful for curing allergic diseases and particularly, asthma.
- US-3 301 859 relates to a process for the production of 2-(1-alkenyl)-4-quinolinols and in particular of 2-(1-nonenyl)-4-quinolinol.
- Examples of the 2, 3-disubstituted-4-hydroxyquinoline derivative according to the invention include: 2-(trans-1-nonenyl)-3-methyl-4-acetoxyquinoline, 2-(trans-1-nonenyl)-3-methyl-4-quinolone, 2-(cis-1-nonenyl)-3-methyl-4-acetoxyquinoline, 2-(cis-1-nonenyl)-3-methyl-4-quinolone, 2-(trans-2-nonenyl)-3-methyl-4-acetoxyquinoline, 2-(trans-2-nonenyl)-3-methyl-4-quinolone, 2-(1-hydroxy-2-nonynyl)-3-methyl-4-acetoxyquinoline, 2-(1-hydroxy-2-nonynyl)-3-methyl-4-quinolone, 2-(trans-1-hydroxy-2-nonynyl)-3-methyl-4-acetoxyquinoline, 2-(trans-1-hydroxy-2-nonynyl)-3-methyl-4-acetoxyquinoline, 2-(
- This reaction can be carried out by subjecting the compound of the general formula (II) to direct reaction with the compound of the general formula (III) including a metal alkene or metal alkyne such as, for example, octenyl lithium, octynyl lithium, lithium di(octenyl)cuprate, lithium di(octynyl)cuprate, lithium octenylmethylcuprate, lithium octynylmethyl cuprate and the like, in an ether solvent at a temperature from room temperature to -20°C.
- a metal alkene or metal alkyne such as, for example, octenyl lithium, octynyl lithium, lithium di(octenyl)cuprate, lithium di(octynyl)cuprate, lithium octenylmethylcuprate, lithium octynylmethyl cuprate and the like, in an ether solvent at a temperature from room temperature to -20°C.
- the reaction may be carried out after reaction in the above-indicated solvent between octene or octyne and a metal hydride such as, for example, sodium hydride, potassium hydride or the like, a metal alkoxide such as potassium butoxide, magnesium ethoxide, a Grignard reagent, diisobutylaluminum hydride, butyl lithium or the like to form a metal alkene or metal alkyne in the reaction solution.
- a metal hydride such as, for example, sodium hydride, potassium hydride or the like
- a metal alkoxide such as potassium butoxide, magnesium ethoxide, a Grignard reagent, diisobutylaluminum hydride, butyl lithium or the like to form a metal alkene or metal alkyne in the reaction solution.
- the compound represented by the general formula (III) and reaction conditions used for the above preparation are similar to those used for the reaction of the compound of the general formula (II) and the compound of the general formula (III) set out before.
- the 3-methyl substituted compound among the starting 2-formyl-3-substituted-4-(hydroxy or acyloxy) quinoline derivatives represented by the general formula (II) can be prepared by subjecting aniline to dehydration condensation with ethyl 2-methylacetoacetate to form a 3-anilino-2-methylcrotonic acid derivative, followed by intramolecular cyclization by heating to high temperature of, preferably, 200 to 250°C to obtain 2, 3-dimethyl-4-quinoline.
- this compound may be further reacted with an anhydrous alkanoic acid such as, for example, acetic anhydride, to obtain 2, 3-dimethyl-4-acyloxyquinoline, e.g. 2, 3-dimethyl-4-acetoxyquinoline, followed by oxidation with selenium dioxide in an aqueous organic solvent to obtain the derivative.
- an anhydrous alkanoic acid such as, for example, acetic anhydride
- Another starting compound used in the process of the invention which is the 2-halogenomethyl-3, 4-disubstituted hydroxyquinoline derivative represented by the general formula (VI) can be prepared by oxidizing the above-obtained 2, 3-dimethyl-4-acyloxyquinoline with m-chloroperbenzoic acid in an organic solvent to obtain a 4-acyloxyquinoline-N-oxide derivative, followed by chlorination with phosphorus oxychloride in a non-aqueous organic solvent to obtain 2-chloromethyl-3-methyl-4-acyloxyquinoline.
- the above-obtained 2-chloromethyl-3-methyl-4-acyloxyquinoline is reacted with sodium iodide or sodium bromide in an aqueous solvent in the preparation.
- the 2, 3-disubstituted-4-hydroxyquinoline derivatives of this invention are substances which show physiological activity on the immune system and cardiac blood system which are important for life conservation of mammals including human beings. As the influence on the immune system, the antagonistic action on leukotriene D4 is very remarkable.
- reaction solution was poured into 100 ml of water, extracted with ethyl acetate and dried with sodium sulfate.
- the reaction temperature was raised from -78°C to room temperature and the reaction solution was stirred at room temperature for 15 minutes.
- the solution was added to a solution of 15 ml of 1N hydrochloric acid and 100 ml of water and filtered through Celite, followed by extraction with ethyl acetate, washing with water and then with a saturated sodium chloride aqueous solution, and drying with sodium sulfate.
- reaction solution was poured into 50 ml of water, extracted with ethyl acetate and dried with sodium sulfate.
- reaction solution was added to 100 ml of water and filtered through Celite, followed by extraction with ethyl acetate, washing with water and a saturated sodium chloride aqueous solution, and drying with anhydrous magnesium sulfate.
- the compounds of the invention have significant antagonistic action on leukotriene D4 and can suppress the contraction of the organ.
- Leukotriene D4 is a substance which is released in allergic diseases. With asthma, for example, it has the action of contracting the bronchial tube and the compounds of the invention are thus effective in suppressing a spasm of asthma.
- mice were intravenously dosed with 50 mg of each test sample. After 30 minutes, the mice were placed in a cage which was reduced to 20 mmHg to measure a surviving time (in seconds). A group of mice which were not dosed with any test sample were provided as a control.
- Test samples Compounds (1), (3), (4) and (10) in Examples.
- Results The results are shown in Table 2.
- Table 2 Test Sample Mouse Surviving Time (seconds) Compound (1) 461 Compound (3) 293.5 Compound (4) 239.5 Compound (10) 206 Control 122.2
- the compounds of the invention can increase the blood flow to the brain and can significantly prolong the brain death time in an anoxic condition. Accordingly, they are effective for curing asphyxiation or brain diseases such as carbon monoxide intoxication.
- novel 2, 3-disubstituted-4-hydroxyquinoline derivatives of the invention have both the antagonistic action on leukotriene D4 and the action of increasing the blood flow of the brain from the heart. Hence, these compounds effectively act on the immune system and the blood flow of the heart which are important for the life maintenance of mammals including human beings and are very effective for curing immunological diseases and brain diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
- This invention relates to novel 4-hydroxyquinoline derivatives which have been found during the course of systematic studies of 2,3-disubstituted-4-hydroxyquinoline derivatives and which have antagonistic action on leukotriene D₄ and also to a process for chemically preparing same. The novel 2,3-disubstituted-4-hydroxyquinoline derivatives of the invention strongly antagonize leukotriene D₄ which is energized in the body of mammals in allergic state and has the action of shrinking organs and are thus useful for curing allergic diseases and particularly, asthma.
- Several 2,3-disubstituted-4-hydroxyquinolines have been heretofore isolated as metabolites from microorganisms such as Pseudomonas pyocyaneum [Journal of Antibiotics (J.A.) 39, 1160 (1986) and Chemical Pharmaceutical Bulletin 15, 718 (1967)]. However, some of these compounds have the disadvantage that the production efficiency by the microorganism fermentation is very low and their invariable supply is difficult in some cases.
- Several 2,3-disubstituted-hydroxyquinoline compounds having an unsaturated hydrocarbon chain at the 2 position are known including 2-(1-heptenyl)-4-quinolone [Journal of Biological Chemistry 159, 725 (1945)], 2-(2-heptenyl)-3-methyl-4-quinolone, 2-(3,6-nonadienyl)-4-quinolone [Chemical Pharmaceutical Bulletin 15, 718 (1967)], 2-(4-heptenyl)-4-quinolone (Phytochemistry 9, 1283 (1970)].
- Chemical Abstracts Vol. 86 (1977), 86:29964d concerns 2-(1-heptenyl)-4-quinolone as a new metabolite of Pseudomonas aeruginosa.
- US-3 301 859 relates to a process for the production of 2-(1-alkenyl)-4-quinolinols and in particular of 2-(1-nonenyl)-4-quinolinol.
- However, no effective process of preparing 2, 3-disubstituted-4-hydroxyquinoline having an alkyl, alkenyl or alkynyl group at the 2 or 3 position has ever been known up to now.
- Moreover, it is known that among the 3-substituted-4-hydroxyquinoline derivatives isolated as a metabolite of microorganism, those having a residue of acrylic acid or its ester at the 3 position is antagonistic against leukotriene D₄, but its activity is generally weak (European Patent Application No. 55068). The 4-quinolone compounds isolated as the metabolite of microorganism have an alkyl or alkenyl group having 7 - 9 carbon atoms at the 2 or 3 position.
- It is an object of the invention to provide novel 2, 3-disubstituted-4-hydroxyquinoline derivatives which have higher antagonistic action on leukotriene D₄ than known 4-quinolone compounds.
- It is another object of the invention to provide a process for preparing a series of compounds including the metabolites of microorganism and its analogues through chemical reactions.
- It is a further object of the invention to provide a process for preparing novel 2, 3-disubstituted-4-hydroxyquinoline derivatives which have higher antagonistic action on leukotriene D₄ than known 4-quinolone compounds.
- According to the invention, there is provided a 2, 3-disubstituted-4-hydroxyquinoline derivative of the general formula (I):
wherein R¹ represents a hydrogen atom or R³CO-, wherein R³ is a lower alkyl group having preferably 1 to 5 carbon atoms ; R² represents a hydrogen atom, -CH₃ or C₂H₅; A represents
-CH₂CH = CH- ,
-CH = CHCH₂- or CH₂C ≡ C- ;
and W represents a hydrogen atom, or halogen atoms, having the strong antagonistic action on leukotriene D₄ and there is also provided a process for preparing such a derivative as defined above and analogous compounds thereof. - The 2, 3-disubstituted-4-hydroxyquinoline derivatives of the general formula (I) having the physiological activity wherein R¹ is a hydrogen is a tautomer relative to the 2, 3-disubstituted-4-quinolone derivative of the formula (VIII):
wherein R², A and W have, respectively, the same meanings as defined before. As a matter of course, the compound of the formula (VIII) is also within the scope of the invention. - Examples of the 2, 3-disubstituted-4-hydroxyquinoline derivative according to the invention include:
2-(trans-1-nonenyl)-3-methyl-4-acetoxyquinoline,
2-(trans-1-nonenyl)-3-methyl-4-quinolone,
2-(cis-1-nonenyl)-3-methyl-4-acetoxyquinoline,
2-(cis-1-nonenyl)-3-methyl-4-quinolone,
2-(trans-2-nonenyl)-3-methyl-4-acetoxyquinoline,
2-(trans-2-nonenyl)-3-methyl-4-quinolone,
2-(1-hydroxy-2-nonynyl)-3-methyl-4-acetoxyquinoline,
2-(1-hydroxy-2-nonynyl)-3-methyl-4-quinolone,
2-(trans-1-hydroxy-2-nonynyl)-3-methyl-4-acetoxyquinoline,
2-(trans-1-hydroxy-2-nonynyl)-3-methyl-4-quinolone,
2-(trans-2-nonenyl)-3-methyl-4-propionyloxyquinoline,
2-(trans-1-nonenyl)-3-methyl-4-propionyloxyquinoline,
2-(trans-1-hydroxy-2-nonenyl)-3-methyl-4-propionyloxyquinoline,
2-(trans-2-nonenyl)-3-methyl-4-butyryloxyquinoline,
2-(trans-1-nonenyl)-3-methyl-4-butyryloxyquinoline,
2-(1-hydroxy-2-nonynyl)-3-methyl-4-butyryloxyquinoline
2-(trans-2-nonenyl)-3-ethyl-4-acetoxyquinoline,
2-(trans-1-nonenyl)-3-ethyl-4-acetoxyquinoline
2-(trans-1-hydroxy-2-nonynyl)-3-ethyl-4-acetoxyquinoline,
2-(1-hydroxy-2-nonenyl)-3-ethyl-4-acetoxyquinoline,
2-(trans-2-nonenyl)-3-ethyl-4-propionyloxyquinoline,
2-(trans-1-nonenyl)-3-ethyl-4-propionyloxyquinoline,
2-(trans-2-nonenyl)-3-ethyl-4-butyryloxyquinoline,
2-(trans-1-nonenyl)-3-ethyl-4-butyryloxyquinoline,
2-(trans-2-nonenyl)-3-ethyl-4-quinolone,
2-(trans-1-nonenyl)-3-ethyl-4-quinolone,
2-(trans-1-hydroxy-2-nonenyl)-3-ethyl-4-quinolone,
2-(1-hydroxy-2-nonynyl)-3-ethyl-4-quinolone,
2-(trans-1-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline,
2-(trans-1-nonenyl)-3-methyl-6-fluoro-4-quinolone,
2-(trans-2-nonenyl)-3-methyl-4-actoxy-6-fluoroquinoline,
2-(trans-2-nonenyl)-3-methyl-6-fluoro-4-quinolone,
2-(1-hydroxy-2-nonynyl)-3-methyl-4-actoxy-6-fluoroquinoline, 2-(1-hydroxy-2-nonynyl)-3-methyl-4-acetoxy-6-fluoroquinoline, 2-(1-hydroxy-2-nonynyl)-3-methyl-6-fluoro-4-quinolone, 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline, 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-6-fluoro-4-quinolone,
2-(trans-1-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline, and the like. - For the preparation of the 2, 3-disubstituted-4-hydroxyquinoline derivatives of the invention wherein the substituent at the 2-position is 1-hydroxy-2-nonenyl group or 1-hydroxy-nonynyl group represented by the following formula (IV):
wherein B represents
R¹ and R² have, respectively, the same meanings as defined before , and W' represents a hydrogen atom or 1 -4 halogen atoms, there are reacted a compound of the general formula (II):
wherein R¹, R² and W' have, respectively, the same meanings as defined before , and a compound of the general formula (III),
Y(-Z(CH₂)₅CH₃)n (III)
wherein Y represents Li, Na, K, Mg, LiCu, R⁴₂Aℓ or R⁴CuLi, wherein R⁴ represents an alkyl or alkenyl group having 1 - 8 carbon atoms ; Z represents -CH=CH- or -C≡C-; and n is a valence of the metal Y . - This reaction can be carried out by subjecting the compound of the general formula (II) to direct reaction with the compound of the general formula (III) including a metal alkene or metal alkyne such as, for example, octenyl lithium, octynyl lithium, lithium di(octenyl)cuprate, lithium di(octynyl)cuprate, lithium octenylmethylcuprate, lithium octynylmethyl cuprate and the like, in an ether solvent at a temperature from room temperature to -20°C. Alternatively, the reaction may be carried out after reaction in the above-indicated solvent between octene or octyne and a metal hydride such as, for example, sodium hydride, potassium hydride or the like, a metal alkoxide such as potassium butoxide, magnesium ethoxide, a Grignard reagent, diisobutylaluminum hydride, butyl lithium or the like to form a metal alkene or metal alkyne in the reaction solution.
- By the above reaction, the compound of the general formula (IV) can be prepared.
- For the preparation of the 2,3-disubstituted-4-hydroxyquinoline derivatives of the present invention wherein the substituent at the 2 position is 1-nonenyl group, i. e., the compound of -CH=CH(CH₂)₆CH₃ represented by the following general formula (V):
wherein R¹, R² and W' have, respectively, the same meanings as defined before , the compound of the general formula (II) and a compound of the following formula:
wherein X represents a halogen atom, and Ph represents a phenyl group , are subjected to the ordinary Wittig reaction. It is preferred that the phosphonium salt is treated with an inorganic base such as, for example, sodium hydride, butyl lithium or the like, for conversion to a corresponding ylide which is used for the above reaction. - For the preparation of the 2, 3-disubstituted-4-hydroxyquinoline derivatives of the present invention wherein the substituent at the 2 position is 2-nonenyl group or 2-nonynyl group, i. e., the compound of -CH₂-CH=CH (CH₂)₅CH₃ or -CH₂-C≡C(CH₂)₅CH₃ represented by the following general formula (VII):
wherein R¹, R², W' and Z have, respectively, the same meanings as defined before , there are reacted the compound of the general formula (VI):
wherein X, R¹, R² and W' have, respectively, the same meanings as defined before , and the compound of the general formula (III),
Y(Z-(CH₂)₅CH₃)n (III)
wherein Y, Z and n have, respectively, the same meanings as defined before . - The compound represented by the general formula (III) and reaction conditions used for the above preparation are similar to those used for the reaction of the compound of the general formula (II) and the compound of the general formula (III) set out before.
- In the process of the invention, the 3-methyl substituted compound among the starting 2-formyl-3-substituted-4-(hydroxy or acyloxy) quinoline derivatives represented by the general formula (II) can be prepared by subjecting aniline to dehydration condensation with ethyl 2-methylacetoacetate to form a 3-anilino-2-methylcrotonic acid derivative, followed by intramolecular cyclization by heating to high temperature of, preferably, 200 to 250°C to obtain 2, 3-dimethyl-4-quinoline. Moreover, this compound may be further reacted with an anhydrous alkanoic acid such as, for example, acetic anhydride, to obtain 2, 3-dimethyl-4-acyloxyquinoline, e.g. 2, 3-dimethyl-4-acetoxyquinoline, followed by oxidation with selenium dioxide in an aqueous organic solvent to obtain the derivative.
- Another starting compound used in the process of the invention which is the 2-halogenomethyl-3, 4-disubstituted hydroxyquinoline derivative represented by the general formula (VI) can be prepared by oxidizing the above-obtained 2, 3-dimethyl-4-acyloxyquinoline with m-chloroperbenzoic acid in an organic solvent to obtain a 4-acyloxyquinoline-N-oxide derivative, followed by chlorination with phosphorus oxychloride in a non-aqueous organic solvent to obtain 2-chloromethyl-3-methyl-4-acyloxyquinoline.
- For the conversion of the chloromethyl group at the 2 position to another halogenomethyl group, the above-obtained 2-chloromethyl-3-methyl-4-acyloxyquinoline is reacted with sodium iodide or sodium bromide in an aqueous solvent in the preparation.
- The 2, 3-disubstituted-4-hydroxyquinoline derivatives of this invention are substances which show physiological activity on the immune system and cardiac blood system which are important for life conservation of mammals including human beings. As the influence on the immune system, the antagonistic action on leukotriene D₄ is very remarkable.
- The present invention is described in more detail in following examples and preparatory examples for starting compounds.
- 0.29 ml of a hexane solution of 0.48 mmols of n-butyl lithium was added to a solution of 218 mg (0.48 mmols) of octyltriphenylphosphonium bromide in 3 ml of tetrahydrofuran and stirred at room temperature for 5 minutes.
- This solution was cooled to -78°C, after which 1.43 g (8 mmols) of hexamethylphosphorus triamide was added and stirred for 5 minutes, followed by further addition of 2 ml of a tetrahydrofuran solution of 91.6 mg (0.40 mmols) of 2-formyl-3-methyl-4-acetoxyquinoline and stirring at -78°C for 15 minutes and subsequently at -42°C for 30 minutes. The reaction mixture was added to 20 ml of water and extracted with ethyl acetate, followed by washing with a saturated sodium chloride aqueous solution and drying with sodium sulfate. After removal of the solvent by distillation under the reduced pressure, the residue was purified by silica gel column chromatography [Wako Gel C-200 (available from Wako Junyaku Co., Ltd.) (solvent n-hexane : ethyl acetate = 15: 1)] to obtain 13 mg of 2-(trans-1-nonenyl)-3-methyl-4-acetoxyquinoline (yield 10%) and 15 mg of 2-(cis-1-nonenyl)-3-methyl-4-acetoxyquinoline (yield 12%).
- Melting point 74 - 75°C
NMR (CDCl₃)
δ=0.90 (t, J=7Hz, 3H), 1.2 - 1.5 (m, 10H), 2.31 (s, 3H), 2.33 - 2.40 (m, 2H), 2.51 (s, 3H), 6.80 (d, J=15.4Hz, 1H), 7.08 (dt, J=15.4Hz, J=7.1Hz, 1H), 7.4 - 7.8 (m, 3H), 8.04 (d, J=8.8Hz, 1H) - MMR (CDCl₃)
δ=0.84(t, J=6Hz, 3H), 1.1 - 1.6 (m, 10H), 2.2 - 2.7 (m, 2H), 2.26 (s, 3H), 2.49 (s, 3H), 6.02 (dt, J=12Hz, J=7Hz, 1H), 6.61 (d, J=12Hz, 1H), 7.3 - 8.1 (m, 4H) - 30 ml of an aqueous solution of 6.30 g (45.6 mmols) of potassium carbonate was added to a solution of 2.47 g (7.60 mmols) of 2-(trans-1-nonenyl)-3-methyl-4-acetoxyquinoline, 250 ml of methanol and 50 ml of water and stirred at room temperature for 13 hours. This solution was neutralized with 1N hydrochloric acid, after which the solvent was distilled off under the reduced pressure, to which 100 ml of chloroform was added, followed by washing with water and drying with sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 1 : 2) to obtain 1.66 g (yield 77%) of 2-(trans-1-nonenyl)-3-methyl-4-quinolone.
Melting point 152 - 153°C
EI-MS m/e 283(M⁺)
NMR (CDCl₃)
δ=0.86 (t, J=7Hz, 3H), 1.1 - 1.5 (m, 10H), 2.13 - 2.19 (m, 2H), 2.22 (s, 3H), 6.56 (dd, J=16.02Hz, J=5.47Hz, 1H), 6.62 (d, J=16.02Hz, 1H), 7.22 - 7.26 (m, 1H), 7.49 - 7.54 (m, 1H), 7.70 (d, J=7.8Hz, 1H), 8.33 - 8.35 (m, 1H), 10.40 (bs, 1H) - 205 mg (1.49 mmols) of potassium carbonate and 2 ml of water were added to a solution of 483 mg (1.49 mmols) of 2-(cis-1-nonenyl)-3-methyl-4-acetoxyquinoline, 1 ml of water and 30 ml of methanol and stirred at room temperature for 13 hours. Thereafter, the solution was treated and purified in the same manner as in Example 2 to obtain 360 mg (yield 86%) of 2-(cis-1-nonenyl)-3-methyl-4-quinolone.
Melting point 170 - 171°C
NMR (CDCl₃)
δ=0.82 (t, J=6Hz, 3H), 1.0 - 1.5 (m, 10H), 2.06 (s, 3H), 2.07 - 2.30 (m, 2H), 5.89 (dt, J=12Hz, J=7.5Hz, 1H), 6.33 (d, J=12Hz, 1H), 7.1 - 7.6 (m, 2H), 8.33 (d, J=7.5Hz, 1H), 9.15 (bs, 1H) - 10 ml of a pentane solution of 15.6 mmols of t-butyl lithium was added to 15 ml of 1.86 g (7.8 mmols) of trans-1-iodo-1-octene ether solution in an atmosphere of argon at -78°C and stirred at the same temperature for 2 hours. The reaction solution was added to 15 ml of an ether solution of 590 mg (3.10 mmols) of copper iodide at -78°C , after which it was heated up to -35°C and stirred at the same temperature for 45 minutes. 1.79 g (10 mmols) of hexamethylphosphorus triamide was added to the solution and stirred at -35°C for 10 minutes, to which 10 ml of a tetrahydrofuran solution of 1.02 g (3.00 mmols) of 2-iodomethyl-3-methyl-4-acetoxyquinoline was added, followed by stirring at the same temperature for 30 minutes. The reaction solution was added to a solution of 3 ml of 1N hydrochloric acid and 100 ml of water, followed by filtration through Celite. The resultant filtrate was extracted with chloroform, washed with water and dried with sodium sulfate. The solvent was distilled off under the reduced pressure and the residue was purified by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 15 : 1) to obtain 221 mg (yield 23%) of 2-(trans-2-nonenyl)-3-methyl-4-acetoxyquinoline
EI-MS m/e 325 (M⁺)
¹HNMR (CDCl₃)
δ=0.86 (t, J=6.94Hz, 3H), 1.23 - 1.36 (m, 8H), 2.01 (dt, J=6.66Hz, 2H), 2.28 (s, 3H), 2.50 (s, 3H), 3.75 (d, J=6.2Hz, 2H), 5.50 (dt, J=15.5Hz, J=6.66Hz, 1H), 5.86 (dt, J=15.5Hz, J=6.2Hz, 1H), 7.48 (t, J=8Hz, 1H), 7.64 (t, J=8.3Hz, 1H), 7.70 (d, J=8.3Hz, 1H), 8.05 (d, J=8.3Hz, 1H)
¹³CNMR (CDCl₃)
δ=12.23, 14.03, 20.52, 22.57, 28.80, 29.25, 31.67, 32.61, 40.74, 120.66, 121.43, 121.59, 125.77, 126.26, 128.90, 129.00, 133.10, 147.46, 151.90, 161.62, 167.92 - A solution of 300 mg (2.17 mmols) of potassium carbonate and 3 ml of water was added to a solution of 705 mg (2.17 mmols) of 2-(trans-2-nonenyl)-3-methyl-4-acetoxyquinoline, 10 ml of water and 50 ml of methanol and stirred at room temperature for 10 minutes. This solution was neutralized with 1N hydrochloric acid, after which the solvent was distilled off under the reduced pressure, followed by addition of 50 ml of chloroform, washing with water and drying with sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 1 : 2) to obtain 550 mg (yield 90%) of 2-(trans-2-nonenyl)-3-methyl-4-quinolone.
Melting point 202 - 203°C
EI-MS m/e 283 (M⁺)
NMR (CDCl₃)
δ=0.84 (t, J=6Hz 3H), 1.10 - 1.05 (m, 8H), 1.80 - 2.10 (m, 2H), 2.16 (s, 3H), 3.38 - 3.59 (m, 2H), 5.51 (dt, J=15.3Hz, J=6.5Hz, 1H), 5.61 (dt, J=15.3Hz, J=6.5Hz, 1H), 7.10 - 7.34 (m, 1H), 7.40 - 7.58 (m, 2H), 8.32 (d, J=8.4Hz, 1H), 10.70 (bs, 1H) - 4.9 ml of a hexane solution of 8.00 mmols of n-butyl lithium was added to a solution of 968 mg (8.80 mmols) of 1-octyne in 10 ml of tetrahydrofuran in an atmosphere of nitrogen at 0°C and stirred at the same temperature for 15 minutes. The reaction solution was cooled to -78°C, to which a solution of 10 ml of tetrahydrofuran of 1.83 g (8.00 mmols) of 2-formyl-3-methyl-4-acetoxyquinoline was added, following by heating gradually to room temperature and stirring at room temperature for 1 hour. The reaction solution was poured into 100 ml of water, extracted with ethyl acetate and dried with sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 2 : 1) to obtain 1.50 g (yield 55%) of 2-(1-hydroxy-2-nonynyl)-3-methyl-4-acetoxyquinoline.
NMR (CDCl₃)
δ=0.86 (t, J=6Hz 3H), 1.15 - 1.65 (m, 8H), 2.16 (s, 3H), 2.20 - 2.40 (m, 2H), 6.60 (t, J=2Hz, 1H), 7.16 - 7.66 (m, 3H), 8.23 - 8.40 (m, 1H) - A solution of 611 mg (4.42 mmols) of potassium carbonate in 2.0 ml of water was added to a solution of 1.50 g (4.42 mmols) of 2-(1-hydroxy-2-nonynyl)-3-methyl-4-acetoxyquinoline, 10 ml of water and 100 ml of methanol and stirred at room temperature for 10 minutes. After neutralization with 1N hydrochloric acid, the solvent was distilled off under reduced pressure, followed by addition of 30 ml of chloroform to the resultant residue, washing with water and drying with sodium sulfate. The solvent was distilled off under the reduced pressure, followed by purification by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 1 : 2) to obtain 945 mg (yield 72%) of 2-(1-hydroxy-2-nonynyl)-3-methyl-4-quinolone.
Melting point 148 - 149°C
EI-MS m/e 297 (M⁺)
NMR (CDCl₃)
δ=0.81 (t, J=6Hz 3H), 1.0 - 1.5 (m, 8H), 1.94 (s, 3H), 2.0 - 2.3 (m, 2H), 4.34 (bs, 1H), 5.49 (bs, 1H), 6.9 - 7.5 (m, 3H), 8.21 (d, J=8Hz, 1H), 9.01 (s, 1H) - 13.9 ml of an n-hexane solution of 13.9 mmols of diisobutylaluminium hydride was added to a solution of 1.68 g (1.53 mmols) of 1-octyne in 20 ml of n-hexane in an atmosphere of nitrogen at 0°C and stirred at 50°C for 2 hours. After removal of the solvent by distillation under the reduced pressure, 20 ml of tetrahydrofuran was added, followed by further addition of a solution, in 15 ml of tetrahydrofuran, of 2.66 g (11.6 mmols) of 2-formyl-3-methyl-4-acetoxyquinoline at -78°C. The reaction temperature was raised from -78°C to room temperature and the reaction solution was stirred at room temperature for 15 minutes. The solution was added to a solution of 15 ml of 1N hydrochloric acid and 100 ml of water and filtered through Celite, followed by extraction with ethyl acetate, washing with water and then with a saturated sodium chloride aqueous solution, and drying with sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (solvent: n-hexane : ethyl acetate = 15 : 1) to obtain 2.08 g (yield 52%) of 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-4-acetoxyquinoline.
EI-MS m/e 341 (M⁺)
IR (neat) 3380, 2950, 1770, 1660, 1620, 1600, 1500, 1370, 1200 cm⁻¹
NMR (CDCl₃)
δ=0.86 (t, J=6Hz, 3H), 1.18 - 1.42 (m, 8H), 1.98 - 2.12 (m, 2H) 2.24 (s, 3H), 2.52 (s, 3H), 5.34 (d, J=7.8Hz, 1H), 5.45 (dd, J=16Hz, J=7.8Hz, 1H), 5.75 (bs, 1H), 5.86 (dt, J=16Hz, J=6.8Hz), 7.5 - 7.8 (m, 3H), 8.0 - 8.2 (m, 1H) - A solution of 502 mg (3.63 mmols) of potassium carbonate in 2 ml of water was added to a solution of 1.23 g (3.63 mmols) of 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-4-acetoxyquinoline, 15 ml of water and 80 ml of methanol and stirred at room temperature for 10 minutes. After neutralization by addition of 1N hydrochloric acid, the solvent was distilled off under the reduced pressure and 30 ml of chloroform was added to the resultant residue, followed by washing with water and drying with sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 1 : 2) to obtain 746 mg (yield 69%) of 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-4-quinolone.
Melting point 170 - 171°C
EI-MS m/e 299 (M⁺)
NMR (CDCl₃)
δ=0.83 (t, J=7Hz, 3H), 1.1 - 1.4 (m, 8H), 1.76 (s, 3H), 1.9 - 2.1 (m, 2H), 4.92 (bs, 1H), 5.17 (d, J=6.5Hz, 1H), 5.46 (dd, J=16Hz, J=6.5Hz, 1H), 5.67 (dt, J=16Hz, J=7.3Hz, 1H), 7.03 - 7.10 (m, 1H), 7.21 - 7.34 (m, 1H), 7.35 - 7.48 (m, 1H), 8.21 - 8.31 (m, 1H), 9.11 (s, 1H) - 0.29 ml of hexane solution of 0.48 mmols of n-butyl lithium was added to a solution of 218 mg (0.48 mmols) of octyltriphenylphosphonium bromide in 3 ml of tetrahydrofuran and stirred at room temperature for 5 minutes. This solution was cooled to -78°C, after which 1.43 g (8 mmols) of hexamethylphosphorus triamide was added and stirred for 5 minutes, followed by further addition of 2 ml of a tetrahydrofuran solution of 98.8 mg (0.40 mmols) of 2-formyl-3-methyl-4-acetoxy-6-fluoroquinoline and stirring at -78°C for 15 minutes and -42°C for 30 minutes. The reaction solution was added to 20 ml of water and extracted with ethyl acetate, followed by washing with a saturated sodium chloride aqueous solution and drying with anhydrous sodium sulfate. After removal of the solvent by distillation under the reduced pressure, the residue was purified by silica gel column chromatography (solvent n-hexane : ethyl acetate = 30 : 1) to obtain 14 mg (yield 10 %) of 2-(trans-1-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline.
NMR (CDCl₃)
δ=0.89 (t, 3H, J=5Hz), 1.1 - 1.7 (m, 10H), 2.28 (S, 3H), 2.3 - 2.4 (m, 2H), 2.48 (S, 3H), 6.72 (d, 1H, J=15Hz), 6.87 (dt, 1H, J=6Hz, 15Hz), 7.1 - 7.5 (m, 2H), 7.99 (dd, 1H, J=5Hz, 9Hz) - 1.5 ml of an aqueous solution of 91 mg (0.66 mmols) of potassium carbonate was added to a solution of 226 mg (0.66 mmols) of 2-(trans-1-nonenyl)-3-methyl-4-acetoxyquinoline in 15 ml of methanol and stirred at room temperature for one hour. This solution was neutralized with 1N hydrochloric acid, after which the solvent was distilled off under the reduced pressure, to which 10 ml of chloroform was added, followed by washing with water and drying with anhydrous sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (solvent: n-hexane : ethyl acetate = 2 : 1) to obtain 160 mg (yield 80 %) of 2-(trans-1-nonenyl)-3-methyl-6-fluoro-4-quinolone.
Melting point 192 - 193°C
EI-MS m/e 301 (M⁺)
NMR (CDCl₃)
δ=0.83 (t, 3H, J=5Hz), 1.0 - 1.5 (m, 10H), 1.9 - 2.1 (m, 2H), 2.17 (s, 3H), 6.3 - 6.8 (m, 2H), 7.23 (dt, 1H, J=2Hz, 8Hz), 7.69 (dd, 1H, J=2Hz, 9Hz), 7.89 (dd, 1H, J=2Hz, 9Hz) - 5.99 ml of a pentane solution of 9.34 mmols of t-butyl lithium was added to 1.11 g (4.67 mmols) of trans-1-iodo-1-octene, 15 ml ether solution in an atmosphere of argon at -78°C and stirred at the same temperature for 2 hours. 400 mg (2.10 mmols) of copper iodide was added to the reaction solution, after which it was heated up to -35°C and stirred at the same temperature for 45 minutes. 941 mg (5.25 mmols) of hexamethylphosphorus triamide was added to the solution and stirred at -35°C for 10 minutes, to which 10 ml of a tetrahydrofuran solution of 628 mg (1.75 mmols) of 2-iodomethyl-3-methyl-4-acetoxy-6-fluoroquinoline was added, followed by stirring at the same temperature for 30 minutes. The reaction solution was added to a solution of 2 ml of 1N hydrochloric acid and 100 ml of water, followed by filtration through Celite. The resultant filtrate was extracted with chloroform, washed with water and dried with anhydrous sodium sulfate. The solvent was distilled off under the reduced pressure and the residue was purified by silica gel column chromatography (solvent: n-hexane : ethyl acetate = 15 : 1) to obtain 120 mg (yield 20 %) of 2-(trans-2-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline.
NMR (CDCl₃)
δ=0.83 (t, 3H, J=5Hz), 1.0 - 1.5 (m, 8H), 1.8 - 2.1 (m, 2H), 2.24 (s, 3H), 2.44 (s, 3H), 3.68 (d, 2H, J=5Hz), 5.3 - 5.8 (m, 2H), 7.1 - 7.5 (m, 2H), 7.99 (dd, 1H, J=5Hz, 9Hz) - A solution of 24 mg (0.17 mmols) of potassium carbonate and 1 ml of water was added to a solution of 60 mg (0.17 mmols) of 2-(trans-2-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline in 8 ml of methanol and stirred at room temperature for 10 minutes. This solution was neutralized with 1N hydrochloric acid, after which the solvent was distilled off under the reduced pressure, followed by addition of 10 ml of chloroform, washing with water and drying with anhydrous sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (solvent: n-hexane : ethyl acetate = 1 : 1) to obtain 46 mg (yield 87 %) of 2-(trans-2-nonenyl)-3-methyl-6-fluoro-4-quinolone.
Melting point 214 - 215 °C
EI-MS m/e 301 (M⁺)
NMR (CDCl₃)
δ=0.85 (t, 3H, J=7Hz), 1.20 - 1.32 (m, 8H), 1.97 - 2.03 (m, 2H), 2.18 (s, 3H), 3.51 (d, 2H, J=5.9 Hz), 5.51 (dt, 1H, J=5.9 Hz, 15.2 Hz), 5.60 (dt, 1H, J=6.3 Hz, 15.2 Hz), 7.27 - 7.32 (m, 1H), 7.60 (dd, 1H, J=4.5 Hz, 9.2 Hz), 7.98 (dd, 1H, J=3.0 Hz, 9.2 Hz), 11.0 (s, 1H) - 1.32 ml of a hexane solution of 2.16 mmols of n-butyl lithium was added to a solution of 238 mg (2.16 mmols) of 1-octyne and 5 ml of tetrahydrofuran in an atmosphere of nitrogen at 0°C and stirred at the same temperature for 15 minutes. The reaction solution was cooled to -78°C, to which a solution of 10 ml of tetrahydrofuran of 445 mg (1.80 mmols) of 2-formyl-3-methyl-4-acetoxy-6-fluoroquinoline was added, followed by heating gradually to room temperature and stirring at room temperature for 1 hour. The reaction solution was poured into 50 ml of water, extracted with ethyl acetate and dried with sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (Wako gel C-200) (solvent: n-hexane : ethyl acetate = 5 : 1) to obtain 349 mg (yield 54 %) of 2-(1-hydroxy-2-nonynyl)-3-methyl-4-acetoxy-6-fluoroquinoline.
NMR (CDCl₃)
δ=0.83 (t, 3H, J=5Hz), 1.0 - 1.7 (m, 8H), 2.0 - 2.2 (m, 2H), 2.33 (s, 3H), 2.49 (s, 3H), 5.4 - 5.8 (m, 2H), 7.1 - 7.5 (m, 2H), 8.02 (dd, 1H, J=5Hz, 9Hz) - A solution of 135 mg (0.978 mmols) of potassium carbonate in 1 ml of water was added to a solution of 349 mg (0.978 mmols) of 2-(1-hydroxy-2-nonynyl)-3-methyl-4-acetoxy-6-fluoroquinoline, 20 ml of methanol and 2 ml of water and stirred at room temperature for 10 minutes. After neutralization with 1N hydrochloric acid, the solvent was distilled off under the reduced pressure, followed by addition of 20 ml of chloroform to the resultant residue, washing with water and drying with sodium sulfate. The solvent was distilled off under the reduced pressure, followed by purification by silica gel column chromatography (Wako gel C-200) (solvent: n-hexane : ethyl acetate = 1 : 1) to obtain 183 mg (yield 59 %) of 2-(1-hydroxy-2-nonynyl)-3-methyl-6-fluoro-4-quinolone.
Melting point 153 - 154°C
EI-MS m/e 315 (M⁺)
NMR (CD₃OD)
δ=0.83 (t, 3H, J=5Hz), 1.1 - 1.7 (m, 8H), 2.17 (s, 3H), 2.2 - 2.5 (m, 2H), 3.30 (bs, 1H), 5.66 (t, 1H, J=2Hz), 7.41 (ddd, 1H, J=3Hz, 8Hz, 9Hz), 7.7 - 7.9 (m, 2H) - 10.8 ml of an n-hexane solution of 10.8 mmols of diisobutylaluminium hydride was added to a solution of 1.31 g (11.9 mmols) of 1-octyne in 20 ml of n-hexane in an atmosphere of nitrogen and stirred at 50°C for 2 hours. The reaction solution was cooled to -78°C, to which a solution of 2.22 ml (9.00 mmols) of 2-formyl-3-methyl-4-acetoxy-6-fluoroquinoline in 30 ml of tetrahydrofuran was added. The reaction temperature was raised from -78°C to room temperature and the reaction solution was stirred at room temperature for 30 minutes. The reaction solution was added to 100 ml of water and filtered through Celite, followed by extraction with ethyl acetate, washing with water and a saturated sodium chloride aqueous solution, and drying with anhydrous magnesium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (solvent: n-hexane : ethyl acetate = 8 : 1) to obtain 1.86 g (yield 58 %) of 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline.
NMR (CDCl₃)
δ=0.83 (t, 3H, J=5Hz), 1.0 - 1.6 (m, 8H), 2.20 (s, 3H), 2.45 (s, 3H), 5.1 - 5.55 (m, 3H), 5.6 - 6.0 (m, 1H), 7.2 - 7.5 (m, 2H), 8.01 (dd, 1H, J=5Hz, 9Hz) - A solution of 715 mg (5.18 mmols) of potassium carbonate in 3 ml of water was added to a solution of 1.86 g (5.18 mmols) of 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-4-acetoxy-6-fluoroquinoline, 50 ml of methanol and 2 ml of water and stirred at room temperature for 10 minutes. After neutralization by addition of 1N hydrochloric acid, the solvent was distilled off under the reduced pressure and 30 ml of chloroform was added to the resultant residue, followed by washing with water and drying with anhydrous sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant residue was purified by silica gel column chromatography (solvent: chloroform : methanol = 40 : 1) to obtain 1.19 g (yield 72 %) of 2-(trans-1-hydroxy-2-nonenyl)-3-methyl-6-fluoro-4-quinolone.
Melting point 163 - 164°C
EI-MS m/e (M⁺)
NMR (CDCl₃)
δ=0.83 (t, 3H, J=7Hz), 1.1 - 1.4 (m, 8H), 1.85 (s, 3H), 1.9 - 2.1 (m, 2H), 4.89 (bs, 1H), 5.27 (bs, 1H), 5.48 (dd, 1H, J=6.5 Hz, 15.4 Hz), 5.73 (dt, 1H, J=6.8 Hz, 15.4 Hz), 7.1 - 7.3 (m, 2H), 7.88 (dd, 1H, J=3Hz, 9Hz), 9.35 (s, 1H) - A solution of 4.30 g (20.0 mmols) of 2,3-dimethyl-4-acetoxyquinoline, 2.44 g (22.0 mmols) of selenium dioxide, 8 ml of water and 80 ml 1,4-dioxane was refluxed for 3 hours. The solvent was distilled off under reduced pressure, after which 100 ml of chloroform was added, followed by washing with a saturated sodium hydrogencarbonate aqueous solution and then with water, and drying with sodium sulfate. The solvent was distilled off under the reduced pressure and the resultant crude product was purified by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 10 : 1) to obtain 2.40 g (yield 52%) of 2-formyl-3-methyl-4-acetoxyquinoline.
Melting point 132 - 133°C
NMR (CDCl₃)
δ=2.52 (s, 3H), 2.59 (s, 3H), 7.5 - 8.3 (m, 4H), 10.3 (s, 1H) - A solution of 4.95 g (23.0 mmols) of 2, 3-dimethyl-4-acetoxyquinoline, 4.76 g (27.6 mmols) of m-chloroperbenzoic acid and 50 ml of methylene chloride was stirred at room temperature for 2 hours, to which was subsequently added 79.4 mg (4.6 mmols) of m-chloroperbenzoic acid, followed by stirring at the same temperature for 3 hours. The reaction solution was washed with a sodium hydrogensulfite aqueous solution, a saturated sodium hydrogencarbonate and finally a saturated sodium chloride aqueous solution, followed by drying with sodium sulfate. The solvent was distilled off under the reduced pressure to obtain 5.42 g of a crude product of 2, 3-dimethyl-4-acetoxyquinoline oxide.
- A solution of 1.38 g (9.04 mmols) of phosphorus oxychloride in 5 ml of methylene chloride and a solution of 913 mg (9.04 mmols) of triethylamine in 5 ml of methylene chloride were, respectively, dropped almost simultaneously in 15 minutes into a solution of 1.85 g (8.00 mmols) of the crude product of 2, 3-dimethyl-4-acetoxyquinoline oxide in 5 ml of methylene chloride, followed by stirring at room temperature for 10 minutes. The reaction solution was washed with a saturated sodium hydrogencarbonate aqueous solution and saturated sodium chloride aqueous solution, and dried with sodium sulfate. The solvent was distilled off under the reduced pressure to obtain a crude product, followed by purification by silica gel column chromatography (Wako Gel C-200) (solvent: n-hexane : ethyl acetate = 5 : 1) to obtain 700 mg (yield 36%) of 2-chloromethyl-3-methyl-4-acetoxyquinoline.
Melting point 108 - 109°C
NMR (CDCl₃)
δ=2.40 (s, 3H), 2.49 (s, 3H), 4.83 (s, 2H), 7.3 - 8.0 (m, 4H) - The antagonistic action on leukotriene D₄ and the mouse life-prolonging action under the reduced pressure of the compounds of the invention are described hereunder.
-
a) Test method
Pieces of the ileum of guinea pig were used and an inhibition rate for their contraction caused by 10 ng/ml of leukotriene D₄ was determined as 2 mcg/ml of a test sample being added.
b) Test samples
Compounds (3), (6), (8) and (10) obtained in Examples.
c) Results
The results are shown in Table 1.Table 1 Test Sample Antagonism on Leukotriene D4 Compound (3) 100 % Compound (6) 100 % Compound (8) 79 % Compound (10) 58 % - As apparent from the above results, the compounds of the invention have significant antagonistic action on leukotriene D₄ and can suppress the contraction of the organ. Leukotriene D₄ is a substance which is released in allergic diseases. With asthma, for example, it has the action of contracting the bronchial tube and the compounds of the invention are thus effective in suppressing a spasm of asthma.
-
a) Test method
Groups of mice, each group consisting of three mice, were intravenously dosed with 50 mg of each test sample. After 30 minutes, the mice were placed in a cage which was reduced to 20 mmHg to measure a surviving time (in seconds). A group of mice which were not dosed with any test sample were provided as a control.
b) Test samples
Compounds (1), (3), (4) and (10) in Examples.
c) Results
The results are shown in Table 2.Table 2 Test Sample Mouse Surviving Time (seconds) Compound (1) 461 Compound (3) 293.5 Compound (4) 239.5 Compound (10) 206 Control 122.2 - As apparent from the above results, the compounds of the invention can increase the blood flow to the brain and can significantly prolong the brain death time in an anoxic condition. Accordingly, they are effective for curing asphyxiation or brain diseases such as carbon monoxide intoxication.
- The novel 2, 3-disubstituted-4-hydroxyquinoline derivatives of the invention have both the antagonistic action on leukotriene D₄ and the action of increasing the blood flow of the brain from the heart. Hence, these compounds effectively act on the immune system and the blood flow of the heart which are important for the life maintenance of mammals including human beings and are very effective for curing immunological diseases and brain diseases.
Claims (4)
- A 2, 3-disubstituted-4-hydroxyquinoline derivative of the general formula (I):
-CH₂CH = CH- ,
and W represents a hydrogen atom, or 1 - 4 halogen atoms. - A process for preparing a 2, 3-disubstituted-4-hydroxyquinoline derivative of the general formula (IV):
Y(-Z(CH₂)₅CH₃)n (III)
wherein Y represents Li, Na, K, Mg, LiCu, R⁴₂Aℓ or R⁴CuLi, wherein R⁴ represents an alkyl or alkenyl group having 1 - 8 carbon atoms ; Z represents -CH=CH- or -C≡C-; and n is a valence of the metal Y . - A process for preparing a 2, 3-disubstituted-4-hydroxyquinoline of the general formula (V):
- A process for preparing a 2, 3-disubstituted-4-hydroxyquinoline compound of the general formula (VII):
Y(-Z(CH₂) ₅CH₃) n (III)
wherein Y represents Li, Na, K, Mg, LiCu, R⁴₂Al or R⁴CuLi, wherein R⁴ represents an alkyl or alkenyl group having 1 - 8 carbon atoms ; Z represents -CH=CH- or -C≡C-; and n is a valence of the metal, Y .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31923188 | 1988-12-17 | ||
JP319231/88 | 1988-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0374765A1 EP0374765A1 (en) | 1990-06-27 |
EP0374765B1 true EP0374765B1 (en) | 1994-06-22 |
Family
ID=18107874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19890123280 Expired - Lifetime EP0374765B1 (en) | 1988-12-17 | 1989-12-15 | 2,3-Disubstituted-4-hydroxyquinoline derivatives and process for preparing the same |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0374765B1 (en) |
DE (1) | DE68916390T2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194617A (en) * | 1988-12-17 | 1993-03-16 | Meiji Seika Kaisha, Ltd. | 2,3-disubstituted-4-hydroxyquinoline derivatives |
US5190952A (en) * | 1989-07-07 | 1993-03-02 | Meiji Seika Kabushiki Kaisha | 4-acyloxyquinoline derivatives and insecticidal or acaricidal compositions containing same |
US6080757A (en) * | 1996-06-06 | 2000-06-27 | Pfizer Inc | Antibiotic quinolones and derivatives |
TW521072B (en) | 1997-06-02 | 2003-02-21 | Meiji Seika Kaisha | 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture |
MX2010003449A (en) | 2007-09-26 | 2010-04-27 | Astellas Pharma Inc | Quinolone derivative. |
ES2664023T3 (en) * | 2013-02-26 | 2018-04-18 | Microbial Chemistry Research Foundation | New compound, its method of production and use of said compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3301859A (en) * | 1963-10-28 | 1967-01-31 | Bristol Myers Co | Cinchoninic acids and use in process for quinolinols |
-
1989
- 1989-12-15 EP EP19890123280 patent/EP0374765B1/en not_active Expired - Lifetime
- 1989-12-15 DE DE1989616390 patent/DE68916390T2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE68916390T2 (en) | 1994-11-17 |
EP0374765A1 (en) | 1990-06-27 |
DE68916390D1 (en) | 1994-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2954954B2 (en) | Substituted 2-pyridones and pyrid-2-thiones, processes for their preparation, and their use in medicine | |
US5120782A (en) | Substituted pyrrolo-pyridines pharmaceuticals | |
NO316676B1 (en) | New tetra-cyclic analogs of camptothecins, their manufacturing processes, their use in the manufacture of drugs and pharmaceutical preparations containing them | |
EP0374765B1 (en) | 2,3-Disubstituted-4-hydroxyquinoline derivatives and process for preparing the same | |
US5194617A (en) | 2,3-disubstituted-4-hydroxyquinoline derivatives | |
CA2011939A1 (en) | 5-substituted-1,4-dihydro-4-oxo-naphthyridine-3-carboxylate antibacterial agents | |
US4576949A (en) | Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein | |
JP7109029B2 (en) | PGE1 core block derivative and method for producing same | |
JP3287845B2 (en) | Method for improving the synthesis of 2,6-dichloro-5-fluoronicotinic acid and 2,6-dichloro-5-fluoronicotinoyl chloride | |
US5137881A (en) | Substituted pyrido-oxazine inhibitors of hmg-coa reductase | |
CZ2012698A3 (en) | Improved process for preparing elvitegravir and novel intermediates of elvitegravir synthesis | |
JP2574489B2 (en) | 2,3-Disubstituted-4-hydroxyquinoline derivatives and process for producing the same | |
Hagen et al. | Synthesis of 5‐methyl‐4‐oxo‐quinolinecarboxylic acids | |
SU1277897A3 (en) | Method of producing 1,1-dioxo-6-brom(or-6,6-dibromine) penicillanoyloxymethyl ethers of 6-(2-azido-2-phenylacetamido)penicillanic acid | |
JP2598921B2 (en) | Novel quinoline derivatives and their salts | |
KR100995882B1 (en) | Process for preparing intermediate of pitavastatin or its salt | |
US5731433A (en) | Process for the preparation of rufloxacin and salts thereof | |
JPS6232753B2 (en) | ||
EP0049144B1 (en) | 5-fluoro uracil derivatives | |
US5112833A (en) | 1-azaindolizine derivatives, synthetic intermediates thereof and antiallergic agents containing 1-azaindolizine derivatives | |
DE19735575A1 (en) | New di:hydroxy-butanal or -pentene derivatives | |
KR100263023B1 (en) | Novel quinolone derivatives with blood lipid lowering action and preparation method thereof | |
RU2002744C1 (en) | Method of synthesis of 1-substituted 6-fluoro-4-oxo-7-(1- piperazinyl)-1,4- -dihydroquinoline-3-carboxylic acid | |
JP2006511469A5 (en) | ||
CZ286679B6 (en) | Derivatives of substituted alkenoic acid, process of their preparation, intermediates for this preparation process, therapeutical agent in which these compounds are comprised as well as their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE FR GB IT |
|
17P | Request for examination filed |
Effective date: 19901219 |
|
17Q | First examination report despatched |
Effective date: 19921208 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE FR GB IT |
|
ITF | It: translation for a ep patent filed | ||
REF | Corresponds to: |
Ref document number: 68916390 Country of ref document: DE Date of ref document: 19940728 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20061207 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20061208 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20061213 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20061231 Year of fee payment: 18 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20071215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080701 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20081020 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071215 |